CD274 and non-small cell lung carcinoma: Even though programmed death ligand 1 (PD-L1) is not a perfect biomarker for response to immunotherapy, patients with locally advanced NSCLC with positive PD-L1 (1 or >1) are likely to benefit from ICIs [6].